Urinary Incontinence, Stress Clinical Trial
Official title:
Randomized Pilot Study on the Treatment of Mixed Urinary Incontinence: Pharmacological Treatment (Tolterodine SR) vs Surgery With Tension Free Vaginal Tape
In patients with symptoms of mixed incontinence (loss of urine associated with
coughing/sneezing/laughing, and loss of urine associated with the strong urge to void), is
surgical treatment with tension free vaginal tape or pharmacological treatment with
tolterodine more effective? What are the parameters predictive of success or failure with
either forms of treatment? What are the parameters predictive of the necessity for further
treatment after primary treatment?
Patients will be randomised to having surgical or pharmacological treatment for their mixed
incontinence symptoms. They will be assessed subjectively and objectively pre-treatment and
after treatment at intervals up to 3 months.
Status | Not yet recruiting |
Enrollment | 40 |
Est. completion date | January 2010 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 35 Years to 70 Years |
Eligibility |
Inclusion Criteria: 1. Patients must be female as this is a urogynaecology study. 2. An age of between 35 and 70 years. This takes into account that incontinence tends to prevail in women with advancing years. Younger women may be planning to start a family which precludes them from participating. 3. Clinical urodynamic evidence of mixed incontinence with prevalence of symptoms of stress incontinence assessed by means of a specific questionnaire and visual analog scale (VAS). The study is assessing the treatment of mixed incontinence and the patients will have to have evidence of this which is provided by their symptoms. 4. Candidates for corrective surgery of the component of sphincter defect with Ba < - 1 according to the International Continence Society (ICS) classification of genital prolapse. 5. Patients capable of filling in the micturition diary, the VAS, and the pathology specific quality of life questionnaire, the Kings Health Questionnaire. These form part of the continuing assessment of effectiveness of treatment. 6. Patients capable of understanding and signing an informed written consent form for participating in the trial. If patients are unable to give their consent for the procedures and investigations they cannot be ethically recruited. 7. Patients who accept not to give birth vaginally in the future, so as not to jeopardize the results of the surgical operation. Exclusion Criteria: 1. Contraindications for using anti-cholinergic agents (urinary retention, uncontrolled narrow-angle glaucoma, myasthenia gravis, severe ulcerative colitis, toxic megacolon). Anticholinergics form one group of the patients and inability to take these drugs therefore precludes them from participating. 2. Ascertained hypersensitivity to tolterodine or any of the excipients. For the above reason. 3. Presence of pathologies or conditions that in the Investigator's opinion make the patient unsuitable for inclusion. 4. Patients with urinary tract infections (UTI) during the run-in period. 5. Patients with recurrent urinary tract infections (> 5 in the past 12 months). 6. Patients with diagnosed interstitial cystitis. These compromise the results obtained. 7. Patients with haematuria of uncertain origin. These patients need urgent investigation of these signs with procedures that are not included in the study. 8. Patients on treatment with anti-cholinergic agents of other drugs acting on detrusor instability. This will compromise the results of the study if for example these patients are randomised into the surgical group. 9. Patients on treatment with oestrogens, unless the therapy was commenced at least 2 months prior to inclusion in the study and follows a constant dosage. 10. Patients on diuretics. This affect their urinary behaviour. 11. Patients on concomitant treatment with potent CYP 34A inhibitors, such as macrolide antibiotics or antimycotic agents. 12. Patients who have undergone previous surgery on the distal urinary tract (with the exception of hysterectomy). 13. Patients who do not have adequate contraceptive cover or patients who are breast-feeding. For reasons of avoiding pregnancy during the study. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United Kingdom | Demetri C Panayi | London |
Lead Sponsor | Collaborator |
---|---|
Imperial College London |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | improvement in subjective and objective measures of urinary incontinence | 3 months | ||
Secondary | assessment of pre-treatment predictors of success or failure of treatment | 3 months | ||
Secondary | assessment of pre-treatment predictors of requirement for alternative treatment | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02001714 -
Group Learning Achieves Decreased Incidents of Lower Urinary Symptoms
|
N/A | |
Completed |
NCT00904969 -
A Pre-Market Study of the American Medical Systems (AMS) Transobturator Male Sling System for the Treatment of Male Stress Urinary Incontinence
|
N/A | |
Completed |
NCT00190814 -
Effectiveness and Safety of Duloxetine in Women Experiencing Urinary Leakage Due to Physical Stress and Urge.
|
Phase 3 | |
Completed |
NCT00190827 -
Effectiveness of Duloxetine in the Treatment of Stress Urinary Incontinence(Uncontrolled Leakage of Urine)
|
Phase 3 | |
Terminated |
NCT00247286 -
Weighted Vaginal Cones Versus Biofeedback in the Treatment of Urodynamic Stress Incontinence: a Randomized Trial.
|
Phase 4 | |
Completed |
NCT01959347 -
Combined Treatment for Mixed Incontinence
|
Phase 3 | |
Completed |
NCT00244296 -
To Determine How Effective Duloxetine is in Treating Women 65 Years and Older With Symptoms of Stress Urinary Incontinence, or With a Combination of Stress Urinary Incontinence and Urge Urinary Incontinence Symptoms
|
Phase 4 | |
Not yet recruiting |
NCT05570071 -
A Study of the Use of Vaginal Radiofrequency Therapy in Treatment of SUI.
|
N/A | |
Completed |
NCT02334878 -
Stem Cell Therapy for Treatment of Female Stress Urinary Incontinence
|
Phase 3 | |
Completed |
NCT01382602 -
Autologous Muscle Derived Cells Female Stress Urinary Incontinence Clinical Study
|
Phase 3 | |
Completed |
NCT03296462 -
Hip External Rotation Physical Therapy Trial
|
N/A | |
Recruiting |
NCT02750878 -
Surgical Consent Process for Trans-obturator Tape Slings.
|
N/A | |
Completed |
NCT02296099 -
Trial Liposomal Bupivacaine Following Retropubic Suburethral Sling for Stress Urinary Incontinence
|
Phase 4 | |
Completed |
NCT02599051 -
Transobturator Verus Single Incision Slings
|
N/A | |
Completed |
NCT00138749 -
An 8 Week Study Looking At The Efficacy, Toleration And Safety Of SS-RBX For Stress Urinary Incontinence.
|
Phase 2 | |
Terminated |
NCT03614611 -
Canadian Experience With Contiform Intravaginal Device For The Treatment Of Stress Incontinence
|
N/A | |
Completed |
NCT03722719 -
The Knack on Female Stress Urinary Incontinence
|
N/A | |
Active, not recruiting |
NCT02275728 -
Pelvic Floor Muscle Training With and Without Biofeedback in Women With Stress Urinary Incontinence
|
N/A | |
Terminated |
NCT01358214 -
Quality of Life After Tension Free Transvaginal Sling / Tape Operation With a Titanized Surgical Tape (TiLOOP® Tape)
|
N/A | |
Active, not recruiting |
NCT01323426 -
Treatment of Stress Urinary Incontinence by Injection of Autologous Muscle Fibers Into the Urethral Sphincter.
|
Phase 1/Phase 2 |